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Major depression is a commonly occurring, seriously impairing, and often 
recurrent mental disorder. Selective serotonin reuptake inhibitors (SSRIs) 
and serotonin-norepinephrine reuptake inhibitors (SNRIs) are the 
treatments most commonly used for major depressive disorder. The 
objective of this study was to assess the cost-effectiveness of SSRIs and 
SNRIs in the treatment of major depressive disorder in two Italian regional 
settings, ie, Veneto and Sardinia. 
Methods 
A decision analytic model was adapted from the Swedish Dental and 
Pharmaceutical Benefits Agency to reflect current clinical practice in the 
treatment of major depressive disorder in the most significant Italian 
regions. This adaptation was possible as a result of collaboration with an 
expert panel of Italian psychiatrists and health economists. The population 
comprised patients with a first diagnosis of major depressive disorder and 
initiating one SSRI or SNRI drug for the first time. The time frame used 
was 12 months. Efficacy and utility data for the model were retrieved from 
the literature and validated by the expert panel. Local data were used for 
resource utilization and for treatment costs based on the perspective of 
each regional health service. Scenario analyses and probabilistic sensitivity 
analyses were performed to test the robustness of the model. 
Results 
Base case analysis showed that escitalopram is associated with the largest 
health gain (in quality-adjusted life years) and a lower total cost at one 
year for Sardinia (except for sertraline, against which it was cost-effective) 
and for Veneto, and therefore dominates the other treatment strategies, 
given that more quality-adjusted life years are achieved at a lower total 
cost. Scenario analyses and probabilistic sensitivity analyses support the 
robustness of the model. 
Conclusion 
The results indicate that escitalopram is the most cost-effective 
pharmacologic treatment strategy for both regional health services 
compared with all SSRIs and all SNRIs used in the first-line treatment of 
major depressive disorder. 
Keywords: antidepressants, major depressive disorder, cost-effectiveness 
quality of life, Italy 
 
Introduction 
Major depressive disorder (MDD) is a commonly occurring heterogeneous 
disorder with a highly variable course, an inconsistent response to 
treatment, and no established physiopathologic mechanism.1 The World 
Health Organization ranked MDD as the principal cause of years lost due 
to disability and the third cause of disability worldwide, projecting that by 
2030 it will be the first leading cause.2 Globally, MDD affects around 150 
million adults, and in Italy the number of people with the disease is 
estimated to be about 5 million with a lifelong prevalence between 8% and 
13%.3 
MDD is considered an important burden in terms of direct costs,4 which 
represent 31% of the total costs, which are paid by patients, their families, 
and the health care services, and also in terms of indirect costs, which 
account for 62% of the overall costs of depression.5,6 In 2004, the 
worldwide economic burden of the disease was estimated at USD 83.1 
billion.7 
MDD is associated with an increased risk of relapse after a first episode 
and a higher risk of suicidal behavior. Depressive disorders impact society 
mainly by increasing suicide risk; in a study of 102 fatal suicides, almost 
70% of victims had had an affective disorder.8 Depressive disorders also 
have a major impact on quality of life. In a study of quality of life 
impairment in depressive disorders, 63% of respondents with MDD had 
severely impaired quality of life, while 56% of those with dysthymia and 
globally 85% of those with double depression (MDD and dysthymia) have 
been reported to have quality of life impairment in the severe range.9 
The main therapeutic alternatives for MDD include antidepressant 
medication, psychotherapy, and neuromodulatory strategies. Selective 
serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine 
reuptake inhibitors (SNRIs) are two classes of antidepressants with a better 
safety profile than the traditional drugs, such as the tricyclic 
antidepressants.10 
A recent literature review by Cipriani et al11 identified differences in 
terms of both efficacy and acceptability among commonly prescribed 
antidepressants in favor of escitalopram and sertraline. In particular, this 
meta-analysis showed that venlafaxine, escitalopram, mirtazapine, and 
sertraline were more effective in terms of response than duloxetine, 
paroxetine, reboxetine, fluoxetine, and fluvoxamine. In terms of 
acceptability, escitalopram, citalopram, bupropion, and sertraline had 
better performance than other second-generation antidepressants. Another 
review by Cipriani et al12 identified some statistically significant 
differences favoring escitalopram over other antidepressive agents for 
acute-phase treatment of major depression in terms of efficacy (citalopram 
and fluoxetine) and acceptability (duloxetine). However, there was 
insufficient evidence to detect a difference between escitalopram and other 
antidepressants in early response to treatment. 
Another paper by Aguglia et al13 reported that use of SSRIs increased 
from 7.5% (2003) to 13.1% (2009) while the utilization of SNRIs 
increased from 0.8% to 2.5%. The most important increase over the 6-year 
period was described for escitalopram (+2.78%). A higher persistence in 
therapy was reported for SSRIs versus SNRIs (15.1% versus 13.0%), and 
escitalopram was associated with the highest percentage of persistent 
patients and the highest number of days of uninterrupted therapy. Overall, 
around 10% of antidepressant users switched their first choice during one 
year of follow-up, while escitalopram was associated with the highest 
frequency of “high” adherers (28.5%).13 
The objective of the present study, called C-QUALITY (Cost and Quality 
of Life Pharmacoeconomic Analysis on MDD in Italy), was to assess the 
cost-effectiveness of SSRI and SNRI drugs used in first-line treatment of 
MDD, adopting Italian Regional Health Service perspectives. In this 
paper, we describe the cases of Veneto and Sardinia. The Italian National 
Health Service (Servizio Sanitario Nazionale) is a complex multitier 
system, involving three different levels of government, ie, central 
(Ministry of Health), regional (Assessorati alla Salute), and local (Aziende 
Sanitarie Locali [ASLs]). The Ministry of Health is responsible for 
national planning and coordination of regional activities, in order to 
guarantee the same essential health care (Livelli Essenziali di Assistenza 
[LEA]) in all areas of the country. Regions are competent to define their 
own health plans so as to organize delivery of services within their own 
territory in accordance with central government planning. The local ASLs 
have administrative and financial autonomy and are directly involved in 
producing and commissioning services in the geographic area under their 
responsibility. Due to regional autonomy, each of them can decide, always 
in accordance with the national level and respecting LEA guidelines, the 
administrative characteristics of their health service in terms of prices of 
the different health services provided (examinations, visits, 
hospitalizations) and cost-sharing rules (copayment, ticket). For these 
reasons, Veneto and Sardinia have been analyzed because of their widely 
different health service costs (examinations, visits, hospitalizations) and 
cost-sharing rules (copayment, ticket) for depression. 
 
Materials and methods 
Description of the model 
An expert panel was organized to evaluate a pharmacoeconomic model 
developed by the Swedish Dental and Pharmaceutical Benefits Agency 
(TLV)14,15 and to adapt it to Italian clinical practice. The panel 
comprised eight psychiatrists from different Italian regions and two health 
economists from an independent agency. Starting from the TLV model, a 
decision analytic model was developed to simulate the management of 
Italian patients with MDD over a time horizon of 12 months. Main inputs 
and parameters of the TLV model, such as decision tree, remission 
probabilities, and utilities, were discussed by the expert panel and adapted 
to the Italian context, with inputs related to costs retrieved as local data. 
This pharmacoeconomic analysis involved patients with a first diagnosis 
of MDD and receiving an SSRI (escitalopram, fluvoxamine, fluoxetine, 
paroxetine, citalopram, sertraline) or SNRI (duloxetine, venlafaxine) 
antidepressant for the first time. The decision tree was developed using 
TreeAge Pro 2011 software (TreeAge Software Inc, Williamstown, MA, 
USA) and its structure is presented in Figure 1. 
The treatment objective was to achieve remission defined by a score of ≤7 
on the Hamilton Depression Rating Scale17 or ≤12 on the Montgomery 
Asberg Depression Rating Scale.18 Once in remission, if the patient did 
not relapse (defined as a new major depressive episode occurring within 6 
months after remission), then she/he was treated with maintenance 
treatment for 6 months in accordance with international treatment 
guidelines; the local expert panel agreed with this treatment pattern. If the 
patient relapsed, it was assumed that relapse occurred within 4 months of 
the start of treatment. Patients who did not respond, defined as not 
achieving remission on first-line treatment, moved to a second-line 
therapy; a proportion of these patients might attempt suicide. Those 
patients who achieved remission in the second step of treatment received 
maintenance treatment for 6 months, whereas those who did not achieve 
remission on second-line treatment moved to the third step of treatment. 
Patients moved to the third and fourth treatment steps according to the 




For the first line of treatment, remission probabilities were estimated 
from an independent meta-analysis conducted by the TLV as specified in 
Table 1. More than 80 studies were included in this meta-analysis for 
around 20,000 patients.14 Further, the authors of the meta-analysis had 
applied adjustments in order to exclude potential bias related to level of 
sponsorship of the studies. The expert panel adapted the second, third, 
and fourth pharmacologic treatment lines described in the STAR*D16 
(Sequenced Treatment Alternatives to Relieve Depression) study to 
standard Italian clinical practice.  
If the initial treatment line failed, patients moved to a second treatment 
line that could be a switching strategy or a combination strategy; if the 
second treatment line failed, patients passed to a third treatment line as an 
augmentation strategy and, finally, if this last strategy also failed, patients 
continued to a fourth treatment line comprising a switching strategy 
carried out during hospitalization (Table 2). 
Treatment lines and strategies considered in the modelRegarding second, 
third, and fourth treatment lines, the expert panel agreed to adapt STAR*D 
remission probabilities to the treatments not considered in the STAR*D 
study, but usually administered in normal Italian clinical practice. 
Remission probabilities of these treatments were assessed as the mean 
value of each drug class considered in the STAR*D study and Mencacci et 
al15 (Table 3). It was assumed that the risk of relapse would be 11% and 
that relapse would occur after 4 months.19 For suicide attempts and the 
probability of dying in such an attempt, a probability value of 0.031 and 
0.1, respectively, was set following the studies by Löthgren and 
Khan20,21 and the work by Mencacci et al15 (Table 4). 
Costs 
Considering the perspective of the model, this analysis took into account 
direct medical costs (drugs, patient examinations, specialist visits, general 
practitioner visits, and hospitalizations) directly reimbursed by the Italian 
Regional Health Service of each study region. 
The expert panel, in order to reflect standard clinical practice in Italy, 
assessed the resource utilization that was applied to the model. They 
suggested a list of examinations that, according to standard clinical 
practice, are usually made at the first visit, ie, electrocardiography, thyroid 
examination, hematology and biochemistry tests, CAT (computed axial 
tomography), and electroencephalography. The expert panel also estimated 
the annual mean number of general practitioner and specialist visits (Table 
5). 
Pharmaceutical costs and resource utilizationLocal data from regional 
outpatient examinations and hospitalization price lists were used to 
estimate diagnosis and treatment costs based on the health service 
perspectives of Veneto and Sardinia. All costs were updated to January 
2013 prices and expressed in Euros. Drug costs were obtained from the 
Italian Drug Agency website22 and drug doses were retrieved from the 
website of the World Health Organization Collaborative Center for Drug 
Statistics Methodology which, according to our expert panel, fit well with 
standard clinical practice in Italy.23 
For the base case analysis, monthly costs were calculated according to the 
defined daily doses whereas an alternative scenario analysis was 
performed calculating monthly costs according to the mean dose (mean of 
minimum and maximum ranges taken from the summary of the product 
characteristics). These costs are shown in Table 5. For each drug 
prescription, a copayment (ticket) paid directly by the patient, when 
applicable, was subtracted from the respective prices. 
 
Utilities 
The TLV model, starting from Sobocki et al,24 adopted a utility value of 
0.81 for a patient who achieves remission and a utility value of 0.57 for a 
patient who does not achieve remission. Moreover, it was assumed that 
utility values for patients who attempt suicide and for those in relapse were 
both equal to the utility value of patients who do not achieve remission 
(0.57). The expert panel did not confirm this approach because, according 
to their clinical experience, these three disease stages have three different 
scores on the rating scales for depression. Based on this assumption, utility 
values were quantified by the expert panel, and these coefficients, 
identified “by consensus”, were associated with the clinical status of 
patients (Table 6). 
UtilitiesNevertheless, the authors decided to test the results by performing 
a scenario analysis using the same utility values as those adopted in the 
TLV model. 
Analyses 
Cost utility analysis, used in this pharmacoeconomic evaluation, is a way 
of measuring the costs and benefits coming from a decision. This 
technique compares the costs of different procedures with their outcomes 
measured in “utility-based” units, ie, units that relate to a person’s level of 
well-being. The most commonly used unit is the quality-adjusted life year 
(QALY). QALYs are calculated by estimating the total life years gained 
from a procedure and weighting each year to reflect the quality of life in 
that year.25 
The incremental cost-effectiveness ratio (ICER) is the ratio of the 
estimated difference between the costs of two interventions and the 
estimated difference between the QALYs of these two interventions. It 
represents the estimated additional cost per extra unit of health generated 
by an intervention compared with its most cost-effective alternative for the 
same health condition. 
Due to the lack of an official willingness-to-pay threshold in Italy, the 
authors decided to use an ICER threshold of €25,000 per QALY, which is 
slightly lower than the one recognized by the National Institute for Health 
and Clinical Excellence.26 We decided to perform the following scenario 
analyses: 
• mean dose calculated from the summary of the product characteristics 
• utility values derived from Sobocki et al.24 
We also performed a probabilistic sensitivity analysis using 10,000 Monte 
Carlo simulations. Gamma distributions were used for costs, except for 
treatment costs in which we applied deterministic costs, while beta-
distributions were applied for all probabilities and utilities of the model. 
 
Results 
Base case analyses 
The results of the cost-effectiveness analysis are shown in Table 7. In the 
Veneto region, the SSRI escitalopram was associated with a lower total 
cost (€1,604.9) compared with all the other treatment strategies, reflecting 
the fact that, on average, patients spend less time in the costly depression 
state. Further, escitalopram was associated with a larger health gain 
(QALYs) at one year (0.732), and therefore dominates the other treatment 
strategies because more QALYs are achieved at a lower total cost. In the 
Sardinia region, escitalopram was associated with a higher health gain 
(QALYs) at one year (0.732) compared with all the other treatment 
strategies whereas, from the cost side, escitalopram was associated with a 
total cost of about €1,138, which was lower than for all the other treatment 
strategies, except for sertraline (€1,122). Therefore, escitalopram 
dominates all the treatment strategies because more QALYs are achieved 
at a lower total cost except for sertraline, against which it was cost-
effective, with an ICER of €2,120.5 per QALY gained. 
Base case resultsFigure 2A and 
andB 
B represent cost-effectiveness planes. Escitalopram was represented as the 
standard strategy because it was the most cost-effective strategy. These 
planes show that all the strategies are located in the third quadrant, 
meaning that they are dominated by escitalopram, except for the cost-
effectiveness plane regarding the Sardinia region, in which sertraline is 
located in the fourth quadrant, meaning that it is less expensive but less 
effective. 
Two alternative scenarios have been tested: the first was the use of a 
different dose for calculating drug costs. We calculated the daily costs of 
the study drugs using the mean dose instead of the defined daily dosage 
used in the base case scenario. The results, shown in Table 8, confirmed 
those from base case with escitalopram dominating all the other 
antidepressants for Veneto. In Sardinia, sertraline was associated with a 
lower cost, followed by venlafaxine extended-release (XR), paroxetine, 
citalopram, fluoxetine, escitalopram, duloxetine, and fluvoxamine. 
Analyzing both the cost and effectiveness of the treatments, venlafaxine 
XR generated an ICER of about €3,728 per QALY gained compared with 
sertraline and escitalopram, which generated an ICER of about €3,402 per 
QALY gained compared with venlafaxine XR. All the other 
antidepressants were dominated. 
Scenario analyses: use of mean doseThe second tested scenario was 
adoption of the utilities derived from Sobocki et al24 used in the TLV 
model. This scenario analysis (Table 9) showed the dominance of 
escitalopram versus the other antidepressants, as also seen in the base case 
analysis for Veneto. Regarding Sardinia, as seen in the base case, 
escitalopram dominated all the other antidepressants except for sertraline, 
against which it was cost-effective, with an ICER of €3,186.6 per QALY 
gained. 
Scenario analyses: use of different utilitiesProbabilistic sensitivity 
analyses 
The cost-effectiveness acceptability curves are presented in Figure 3A and 
andB. 
B. For every value of willingness-to-pay considered, escitalopram is the 
most cost-effective strategy for Veneto. Given a threshold of €25,000 per 
QALY gained, there is around a 34% probability that escitalopram is cost-
effective compared with the other treatments. Furthermore, compared with 
the other treatments, there is a 26% probability that escitalopram is cost-
effective at a willingness-to-pay equal to zero, meaning that it is dominant 
in comparison with the other treatments. 
For the Sardinia health services, escitalopram was the most cost-effective 
antidepressant for a willingness-to-pay of more than €3,000. Considering a 
threshold of €25,000 per QALY gained, there is an around 34% 
probability that escitalopram is cost-effective compared with the other 
treatments. Nevertheless, at a willingness-to-pay equal to zero, 
escitalopram showed a 16% probability of being cost-effective dominating 
the other molecules. 
 
Discussion 
The C-QUALITY Project is the first cost-effectiveness analysis that 
compares all SSRIs and SNRIs in the first-line treatment of MDD in Italy 
and in a regional setting. The results for the Veneto model showed that in 
comparison with the seven antidepressants considered, escitalopram was 
less costly and more effective in terms of QALYs, dominating all the other 
pharmacologic treatments used in first line. The results from the Sardinia 
model showed that escitalopram dominated all the other pharmacologic 
treatments except for sertraline, against which it was cost-effective, 
generating an ICER of €2,120.5 per QALY gained; this value is much 
lower than the €25,000 threshold. Probabilistic sensitivity analyses and 
scenario simulations confirmed these results, indicating the robustness of 
the model. 
Many other analyses14,27–30 fit with the results of this model. In a review 
of the use of antidepressants conducted by the TLV group, Wessling et 
al14 compared the costs and outcomes for first-line treatment with some of 
the most used antidepressants; in this health economics model for 12 
months of treatment in Sweden, the results showed that escitalopram was 
the treatment giving the highest number of QALYs for the lowest cost 
(except for mirtazapine). All the other treatments were dominated by 
escitalopram. A study by Nordström et al27 compared the cost-
effectiveness of escitalopram versus generic venlafaxine XR over a 6-
month time frame for patients with MDD in Sweden. Compared with 
generic venlafaxine XR, escitalopram was found to be less costly and 
more effective in terms of QALYs. 
Ramsberg et al28 developed a model to analyze the cost-effectiveness of 
ten antidepressants. As in our study, remission rates were retrieved from a 
meta-analysis. The perspectives used were the societal and the health care 
service ones, while the time horizon was 12 months. The results showed 
that the most cost-effective pharmacologic treatment from a societal 
perspective was escitalopram, dominating all the other comparators, while 
from a health care perspective, the cost per QALY of escitalopram was 
€3,732 compared with that of venlafaxine. 
The cost-effectiveness analysis presented by Nuijten et al29 compared 
venlafaxine XR, citalopram, and escitalopram from the societal 
perspective in a time horizon fixed at 26 weeks. The study results showed 
that escitalopram was associated with a mean cost saving of €263 per 
patient versus venlafaxine XR and €1,992 versus citalopram. Escitalopram 
was also associated with a gain in QALYs of 0.0062 when compared with 
venlafaxine XR and of 0.0166 if compared with citalopram. Escitalopram 
was therefore dominant over both venlafaxine XR and citalopram. 
Another cost-effectiveness analysis presented by Druais et al,30 also 
adapting the TLV model, compared eight antidepressants from the 
perspectives of both society and the health care service, with a time 
horizon of one year and studying patients with MDD treated with a first-
line antidepressant. The results showed that from the health care 
perspective escitalopram dominated all the other treatments except for 
venlafaxine, against which it was cost-effective, with an ICER of €6,351 
per QALY gained; from the societal perspective, escitalopram dominated 
all the other strategies. 
Several limitations to this study should be noted. For example, the main 
clinical inputs for the model, based on studies not performed in an Italian 
health care setting could be a limitation; nevertheless, the probabilities of 
clinical events are not usually considered to be country-specific.29 
Another limitation regards the information about resource utilization, 
utilities, and treatment lines, that were estimated by the expert panel due to 
the lack of published local data. However, in situations in which the 
published material is insufficient or when literature review is unreliable, it 
has been suggested that use of expert opinion is considered appropriate.31 
Further, sensitivity analyses with available published data have been 
performed, confirming the robustness of the model. 
 
Conclusion 
The presented cost-effectiveness analysis indicates that escitalopram is a 
cost-effective pharmacologic treatment strategy regarding the Veneto and 
Sardinia health services compared with the other SSRIs and SNRIs used in 
the first-line treatment of MDD. This is due to its lower direct costs 
compared with other treatment strategies and its higher effectiveness in 
terms of QALY gains. 
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